Pharsight — Q2 2007 Earnings Presentation
33 slides from Pharsight's earnings presentation, Nov 30, 2006

Slide 1: Pharsight Corporation Investor Presentation 2nd Quarter Fiscal 2007 Update
Pharsight Corporation Investor Presentation 2nd Quarter Fiscal 2007 Update September 30, 2006 Shawn O’Connor President, Chairman and CEO Will Frederick CFO Exhibit 99.1 Confidential © Pharsight Corporation

Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements, including statements regarding our financial model, growth opportunities and strategic investments, our market position, the demand and market opportunity for our products and services, financial and product performanc

Slide 3: Management Team
Management Team Shawn M. O’Connor President, Chairman and Chief Executive Officer QRS, Diasonics Ultrasound, Peat Marwick Will Frederick Chief Financial Officer Versata, Clarent, ACT Networks, Disney James Hayden SVP Global Sales Accelrys, Bio-Rad Laboratories, Raytheon Mark Hovde SVP Marketing Hovd

Slide 4: Market Opportunity
Market Opportunity High throughput screening Combinatorial chemistry Genomics Rational drug design nificant Productivity Increase and Investment en Geapenieed: ‘smal Pharsight Long, risky and complex process Of 5,000 screened compounds: 250 enter preclinical testing, 5 enter clinical testing and 1 i

Slide 5: Market Opportunity: Product Diversification
Market Opportunity Product Diversification • Customers “crossing the chasm” to full use of the Pharsight family of products can create increases of 60x in initial revenue and 15x in ongoing revenue WinNonlin Licenses Before Diversification 4 WNL Pro Users $6K $360K 0 1 2 3 4 5 6 7 8 WNL Enterprise W

Slide 6: FDA Influence
FDA Influence FDA and Pharsight sign CRADA - June 2006 • Pharsight will make available a comprehensive suite of software tools, including: Pharsight ® Knowledgebase Server™ (PKS™), PKS Validation Suite™, WinNonlin ® Validation Suite™, Trial Simulator™ and Drug Model Explorer™ (DMX™). • FDA will use

Slide 7: Software Products
Software Products Confidential © Pharsight Corporation

Slide 8: Key Software Offerings
Key Software Offerings • Analytics – WinNonlin ® – WinNonMix ® – Trial Simulator™ – IVIVC Toolkit™ for WinNonlin • Data Management & Compliance – Pharsight ® Knowledgebase Server™ – PKS Reporter – WinNonlin AutoPilot™ • Validation – WinNonlin Validation Suite™ – PKS Validation Suite™ • Model Visuali

Slide 9: Key Software Offerings: WinNonlin
Key Software Offerings Pharsight Industry Gold-Standard for Pharmacokinetic (“PK”), Pharmacodynamic (“PD”) Modeling, and Non Compartmental Analysis Key Benefits — Used to simulate effects of different dosing regimens and changes in pharmacokinetic parameters required in regulatory submissions - Incr

Slide 10: Key Software Offerings: WinNonMix
Key Software Offerings Pharsight Nonlinear Mixed Effects (Population) Analysis Software Application * Key Benefits - Extensive built-in library of PK, PD and PK-PD models - NONMEM data import wizard - Built-in report-ready graphics capability - Estimation algorithms for sparse and for rich data sets

Slide 11: Key Software Offerings: Trial Simulator
Key Software Offerings Pharsight State-of-the-Art Clinical Trial Design and Simulation Software * Key Benefits — Minimize risk of trial design - Formalize assumptions = Quantify uncertainty - Reduce cost of clinical trials and drug development time-to-market * Potential Growth Drivers - Increase pot

Slide 12: Key Software Offerings: Pharsight Knowledgebase Server
Key Software Offerings Pharsight ® Knowledgebase Server™ (“PKS™”) • Key Benefits – Dramatically improves data management and data access – Increases productivity in analysis and reporting tasks – Supports compliance with FDA requirements for electronic records and signature, CFR 21 part 11 • Potenti

Slide 13: Key Software Offerings: Drug Model Explorer
Key Software Offerings Drug Model Explorer™ (“DMX ® ”) • Key Benefits – Facilitates more efficient collaboration within project teams to explore key drug attributes, and their respective uncertainties – Enables more flexible scenarios and generates views of program data from underlying model outputs

Slide 14: Return on Investment Example
Return on Investment Example “Within 2 years of (implementing Pharsight’s WinNonlin automation and other measures) the two people conducting the routine pharmacokinetic studies had completed 45 studies in 1 year.” (previous staff of 19 for the same work) “The cycle time to issue final reports decrea

Slide 15: Software Products Customers
Software Products Pharsight * Over 1,200 active software customers ¢ All Top 50 Pharma? license at least one of our software products ¢ Our software applications are licensed for use on more than 6,000 desktops in industry and academia * 12 of the Top 50 Pharma? are PKS™ customers - 18 total PKS™ cu

Slide 16: Strategic Consulting Services
Strategic Consulting Services Confidential © Pharsight Corporation

Slide 17: Strategic Consulting Services
Strategic Consulting Services Formal, quantitative, model-based decision-making method Increases drug development productivity Decreases late stage attrition Decreases time-to-market Reduces financial investment Improves clinical quality and commercial performance of final product

Slide 18: Quantitative Modeling Supports Both Trial- and Program-Level Decisions
Quantitative Modeling Supports Both Trial- and Program-Level Decisions Animal PK Data Human PK Data Treatment, Exposure Patient Endpoints Trial Outcomes Market Acceptance Drug and Patient Models Trial Models Market Models • Optimize treatment regimens and patient populations for the market and for a

Slide 19: Overview of Consulting Services
Overview of Consulting Services • World-class experts in clinical pharmacology, PK/PD, decision analysis, and statistics • Senior scientific leadership with extensive drug development experience • Seasoned practitioners from industry, academia, and consulting • Serving all major drug development geo

Slide 20: Strategic Consulting Services: Revenue Diversification
Strategic Consulting Services Revenue Diversification Q2 FY07 50% 50% Top 2 clients Others Q2 FY06 81% 19% Top 2 clients Others $2.7M Revenue $1.9M Revenue Successful Diversification Efforts with Reduced Revenue Dependency on “Top 2 Clients”

Slide 21: Return on Investment Example
Return on Investment Example Aventis turned to a computer model from … Pharsight. Using its own animal and human test data, Aventis was able to simulate later-stage clinical trials. Based on that simulation, “we stopped funding development of the compound. The ratio between the therapeutic benefit a

Slide 22: Financial Overview
Financial Overview Confidential © Pharsight Corporation

Slide 23: Accomplishments and Guidance
Accomplishments and Guidance FY06 Accomplishments • Revenue growth – Y/Y revenue growth of 1% – consecutive year of revenue growth • Gross Margin – 66% of revenue • Profitability – Net income of $530,000 – consecutive year of profitability • Achieved positive annual net cash flow FY07 Guidance • Con

Slide 24: Summary Income Statements
Summary Income Statements (in thousands) Consol. SPBU SCS Consol. SPBU SCS Revenue 6,284 3,553 2,731 5,920 4,005 1,915 Y/Y growth 6% -11% 43% 17% 60% -25% Cost of revenue 1,817 1,464 2,054 1,390 Gross profit 4,467 3,200 1,267 3,866 3,341 Gross margin 71% 90% 46% 65% 83% 27% Operating expenses 3,753

Slide 25: Summary Balance Sheets
Summary Balance Sheets (in thousands) Sep. 30, March 31, Cash & cash equivalents 6,438 $ 10,832 $ Short-term investments 4,749 -- Accounts receivable, net 3,397 4,585 Total current assets 15,170 15,715 Total assets 16,998 $ 17,786 $ LIABILITIES & STOCKHOLDERS' DEFICIT A/P & accrued expenses 3,612 $

Slide 26: Annual Revenue by Business Unit
Annual Revenue by Business Unit (in thousands) $0 $5,000 $10,000 $15,000 $20,000 $25,000 $30,000 FY03 FY04 FY05 FY06 FY07 Guidance Software Products Strategic Consulting Guidance ($25M - $26M)

Slide 27: Quarterly Revenue by Business Unit
Quarterly Revenue by Business Unit (in thousands) $0 $1,000 $2,000 $3,000 $4,000 $5,000 $6,000 $7,000 Q2 FY06 Q3 FY06 Q4 FY06 Q1 FY07 Q2 FY07 Software Products Strategic Consulting

Slide 28: Annual Gross Profit
Annual Gross Profit (in thousands) $0 $2,500 $5,000 $7,500 $10,000 $12,500 $15,000 $17,500 FY02 FY03 FY04 FY05 FY06

Slide 29: Annual Operating Income
Annual Operating Income (in thousands) -$20,000 -$17,500 -$15,000 -$12,500 -$10,000 -$7,500 -$5,000 -$2,500 $0 $2,500 $5,000 FY02 FY03 FY04 FY05 FY06

Slide 30: Annual Operating Cash Flow
Annual Operating Cash Flow (in thousands) -$8,000 -$6,000 -$4,000 -$2,000 $0 $2,000 $4,000 FY02 FY03 FY04 FY05 FY06

Slide 31: Pharsight
Pharsight

Slide 32: Proprietary Notice
Proprietary Notice Pharsight All contents Copyright ©2006 Pharsight Corporation. All rights reserved. The copyright for this document is owned by Pharsight Corporation. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocop

Slide 33: Pharsight
Source: SEC EDGAR · 8-K filed Nov 30, 2006
More decks from Pharsight Corp
Q4 2007 Earnings Presentation45 slides · May 14, 2007
Investor Presentation (January 2007)41 slides · Jan 26, 2007
Q1 FY2007 Earnings Presentation37 slides · Aug 3, 2006
Investor Presentation (June 2006)36 slides · Jun 6, 2006
Investor Presentation (February 2006)31 slides · Feb 2, 2006
Investor Presentation (August 2005)39 slides · Aug 2, 2005